| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 13
| Issue : 1 | Page : 9-15 |
|
|
Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome
Amrallah A Mohammed1, Hani El-Tanni2, Mohammed A Alsakkaf3, Ahmad A Mirza4, Tariq Al-Malki Atiah4, Arwa Al-Malki Atiah4
1 Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Oncology Center, King Abdullah Medical City-Holy Capital, Makkah, Saudi Arabia
2 Oncology Center, King Abdullah Medical City-Holy Capital, Makkah, Saudi Arabia
3 Batterjee Medical College, Jeddah, Saudi Arabia
4 Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
Correspondence Address:
Amrallah A Mohammed
Muzdallifa Streat, P.O. Box 57657, 21995 Mecca, Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.180605
|
|
|
The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of “personalized medicine.” There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
